both in experimental animals (Severinghaus and Lassen, 1967; Lassen, 1968; Cotev et al., 1968; Kong et al., 1969) and in patients suffering from cerebrovascular disease (Posner and Plum, 1960; Ehrenreich et al., 1961; Gotoh et al., 1966) . At effective doses, however, other tissues containing carbonic anhydrase are also affected (Maren, 1963) , and a marked diuresis occurs because of the renal effect (Maren, 1967) . A recently produced CAI 130 ) has a more selective action on the brain, because it crosses the bloodbrain barrier more readily it is more lipophilic and has lower ionization compared with acetazolamide. At doses producing a similar increase in CBF in dogs the diuresis was four times less (Accepted 26 April 1976.) than with acetazolamide. The only study in man showed a significant increase in CBF after intravenous dosage, using the intracarotid injection of radioactive xenon to measure the CBF (Skinh0j, 1975) . This invasive method has limited application and it is difficult to justify repeated measurements. We have therefore used the recently developed inhalation method to make repeated measurements of CBF before and during oral administration of UK-12,130 in demented geriatric patients-a group for whom the drug has been recommended as of possible therapeutic benefit.
METHOD
Seven mildly demented but cooperative female patients aged 67 to 91 years were chosen at the Department of Geriatric Medicine, Royal Alexandra Infirmary, and consent for their inclusion in the trial obtained in writing from relatives. They were brought by car to the Institute of Neurological Sciences, Southern General Hospital, Glasgow at weekly intervals for measurements.
Three separate dosage regimens were employed: Regimen 1 Initial loading dose of 100 mg UK-12, 130. This was followed (four hours later) by 50 mg three times daily. This dosage was continued for two weeks. D. J. Wyper, C. J. McAlpine, K. Jawad, and B. Jennett Regimen 3 Initial loading dose of 100 mg, followed four hours later by 50 mg three times daily for six weeks.
All doses were taken orally. A minimum of four weeks elapsed between the end of one course and the start of another. The purpose of regimen 3 was to investigate possible escape from the effects of the drug.
There were six patients in regimen 1, five of these plus one new patient in regimen 2, and four in regimen 3.
MEASUREMENT OF CEREBRAL BLOOD FLOW Cerebral blood flow was measured using the two-minute slope 133Xe inhalation technique (Wyper et al., 1976) . The patient, who was sitting or lying on a couch, breathed through a rubber mouthpiece. Once a steady respiratory pattern had been obtained, a 32-second count of background radioactivity was recorded; then the two-minute saturation phase began, during which a mixture of '33Xe in air at a concentration of I mCi/l. was inhaled. Clearance of 133Xe from the head was then recorded for 21 minutes, during air breathing using four 2.5 cm (1 in) diameter collimated scintillation detectors. Two detectors were positioned to view the hemispheres from front to back and the other two were positioned on the left side viewing the temporal and parietal regions. The end-expired air concentration of 133Xe was also recorded using a welltype scintillation counter, in order to allow a correction to be made for recirculating xenon. The end-tidal PCO2 was measured using an infra-red C02 analyser.
CBF measurements were made as follows: Regimen I Two measurements before the loading dose then two hours and four hours after the loading dose. One measurement after one week on the regular dosage immediately before that day's first dose. One measurement two hours after this. One measurement after a further week on the regular dose immediately before that day's first dose repeated two hours after this.
Regimen 2 (Fig. la) . For each patient, the average CBF increase after one and two weeks is statistically significant on an individual basis (P < 0.05 as described above).
End-tidal PCO2 was not significantly changed two or four hours after the loading dose but was reduced after one and two weeks by 18.7±3.70o and 19.0 ±4.30o respectively (Fig. lb) (Fig. 2a) . There was no significant difference between the values of two weeks and six weeks (Table 3) . 
End-tidal PCO2 fell by 20.5 ±5.7% and 26.7±4.3% after two and six weeks respectively (Fig. 2b) .
DISCUSSION
This study shows that a significant and persisting increase in the cerebral blood flow occurs after the oral administration of UK-12,130. Repeatability studies indicate that these changes would not be expected in these patients if they did not receive a drug. There was no consistent improvement in mentation associated with the increase in cerebral blood flow.
Increases found in CBF tended to be accompanied by decreases in end-tidal PCO2, but as these were attributed to the effect of the drug it was not considered appropriate to apply corrections to the CBF values to compensate for changes in PCO2. When erythrocyte carbonic anhydrase is inhibited the normal criteria for measuring blood and end-tidal PCO2 do not apply. In the presence of CAI the normally rapid hydration of CO2 (at the tissue capillary) and its dehydration (at the alveolar capillary) is incomplete, resulting in an increased gradient of CO2 from tissue to alveolus, since CO2 cannot reach equilibrium with H2CO3 (Maren, 1967) . Thus, tissue and capillary PCO2 and arterial H2C03 will rise and alveolar PCO2 falls.
An increase in CBF was observed four hours after the loading dose of 130 
